| European Case Law Identifier: | ECLI:EP:BA:2011:T128511.20111215 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 15 December 2011 | ||||||||
| Case number: | T 1285/11 | ||||||||
| Application number: | 08806952.1 | ||||||||
| IPC class: | C07D 213/71 A61K 31/435 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Polymorphs of 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-mehtyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof and methods for making the same | ||||||||
| Applicant name: | Pfizer Products Inc. | ||||||||
| Opponent name: | - | ||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Admissibility of amendments under Rules 137(5) and 164(2) EPC (yes) Substantial procedural violation (yes) - lack of essential reasoning prior to refusal Reimbursement of the appeal fee (yes) Remittal (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t111285eu1.html
Date retrieved: 17 May 2021